NewslettersHepatic Cell NewsImjudo (Tremelimumab) in Combination with Imfinzi Approved in the US for Patients with Unresectable Liver CancerBy Laurisa Dohm - October 28, 20220128AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable HCC.[AstraZeneca Inc.]Press Release